ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 117 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 2.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $2,306,000 | +217.2% | 30,839 | +391.5% | 0.38% | +228.7% |
| Q2 2018 | $727,000 | -11.3% | 6,275 | -38.1% | 0.12% | -16.1% |
| Q1 2018 | $820,000 | -78.5% | 10,138 | -86.5% | 0.14% | -74.2% |
| Q4 2014 | $3,809,000 | +53.3% | 74,915 | +19.4% | 0.53% | +5.3% |
| Q3 2014 | $2,484,000 | -10.6% | 62,768 | -2.8% | 0.50% | -4.4% |
| Q2 2014 | $2,780,000 | +5.6% | 64,554 | -2.0% | 0.53% | +11.2% |
| Q1 2014 | $2,633,000 | +42.6% | 65,846 | -2.8% | 0.48% | +43.5% |
| Q4 2013 | $1,847,000 | – | 67,708 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |